Vimal Mehta, CEO and President at BioXcel Therapeutics, Inc. (BTAI), sold 119,253 shares at $21.41 ($2.5M) on 2023-06-15, disclosed to the SEC on 2023-06-16.
Scheduled sale ($2.5M) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.41 | 21,988 | $471K | 18.9% |
| 2 | $21.41 | 21,988 | $471K | 18.9% |
| 3 | $21.90 | 8,012 | $175K | 7.1% |
| 4 | $21.90 | 8,012 | $175K | 7.1% |
| 5 | $20.01 | 24,987 | $500K | 20.1% |
| 6 | $20.01 | 24,987 |
| $500K |
| 20.1% |
| 7 | $20.90 | 4,266 | $89K | 3.6% |
| 8 | $20.90 | 4,266 | $89K | 3.6% |
| 9 | $21.89 | 747 | $16K | 0.7% |
| Total | $20.86 avg | 119,253 | $2.5M | 100% |
| Filing → |
| BTAI | SELL | 2024-09-17 | $1K | — | Filing → |
| BTAI | SELL | 2024-06-18 | $3K | — | Filing → |
| BTAI | SELL | 2024-04-08 | $14K | — | Filing → |